Your browser doesn't support javascript.
loading
Combined Evidence for a Long-Term, Clinical Slowing Effect of Multinutrient Intervention in Prodromal Alzheimer's Disease: Post-Hoc Analysis of 3-Year Data from the LipiDiDiet Trial.
Hendrix, S B; Soininen, H; Solomon, A; Visser, P J; van Hees, A M J; Counotte, D S; Nicodemus-Johnson, J; Dickson, S P; Blennow, K; Kivipelto, M; Hartmann, T.
Afiliación
  • Hendrix SB; Suzanne B Hendrix, Pentara Corporation, 2180 Claybourne Avenue, Salt Lake City, UT 84109 USA, E-mail: shendrix@pentaracorp.com, Phone: +1 (801) 898-7241.
J Prev Alzheimers Dis ; 10(3): 464-470, 2023.
Article en En | MEDLINE | ID: mdl-37357286
ABSTRACT
The LipiDiDiet randomized clinical trial is evaluating the long term effects of a multinutrient intervention (Fortasyn Connect) compared with control in participants with prodromal AD. In this post-hoc analysis we used the Alzheimer's Disease Composite Score (ADCOMS) as a measure of cognition and global function, together with a global statistical test (GST) and Bayesian hierarchical modelling (BHM) to evaluate the totality of evidence for an effect of the intervention over 36 months. The analysis includes 67 participants (39 active, 28 control) with change from baseline data after 36 months intervention. All outcome measures showed a statistically significant effect for the intervention ADCOMS (P =0.045), GST (P <0.001), and BHM (P =0.008 based on 3 outcomes and P <0.001 including all primary and secondary quantitative clinical outcomes). Fortasyn Connect was associated with significantly less clinical decline over 36 months, suggesting the long-lasting beneficial effects of the multinutrient in prodromal AD.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Enfermedad de Alzheimer Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: J Prev Alzheimers Dis Año: 2023 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Enfermedad de Alzheimer Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: J Prev Alzheimers Dis Año: 2023 Tipo del documento: Article